OBJECTIVE: Plaque necrosis is a key feature of defective resolution in atherosclerosis. Recent evidence suggests that necroptosis promotes plaque necrosis; therefore, we sought to determine how necroptotic cells (NCs) impact resolution programs in plaques. Approach and Results: To investigate the role(s) of necroptosis in advanced atherosclerosis, we used mice deficient of Mlkl, an effector of necroptosis. Mlkl-/- mice that were injected with a gain-of-function mutant PCSK9 (AAV8-gof-PCSK9) and fed a Western diet for 16 weeks, showed significantly less plaque necrosis, increased fibrous caps and improved efferocytosis compared with AAV8-gof-PCSK9 injected wt controls. Additionally, hypercholesterolemic Mlkl-/- mice had a significant increase in proresolving mediators including resolvin D1 (RvD1) and a decrease in prostanoids including thromboxane in plaques and in vitro. We found that exuberant thromboxane released by NCs impaired the clearance of both apoptotic cells and NCs through disruption of oxidative phosphorylation in macrophages. Moreover, we found that NCs did not readily synthesize RvD1 and that exogenous administration of RvD1 to macrophages rescued NC-induced defective efferocytosis. RvD1 also enhanced the uptake of NCs via the activation of p-AMPK (AMP-activated protein kinase), increased fatty acid oxidation, and enhanced oxidative phosphorylation in macrophages. CONCLUSIONS: These results suggest that NCs derange resolution by limiting key SPMs and impairing the efferocytic repertoire of macrophages. Moreover, these findings provide a molecular mechanism for RvD1 in directing proresolving metabolic programs in macrophages and further suggests RvD1 as a potential therapeutic strategy to limit NCs in tissues. Graphic Abstract: A graphic abstract is available for this article.
OBJECTIVE: Plaque necrosis is a key feature of defective resolution in atherosclerosis. Recent evidence suggests that necroptosis promotes plaque necrosis; therefore, we sought to determine how necroptotic cells (NCs) impact resolution programs in plaques. Approach and Results: To investigate the role(s) of necroptosis in advanced atherosclerosis, we used mice deficient of Mlkl, an effector of necroptosis. Mlkl-/- mice that were injected with a gain-of-function mutant PCSK9 (AAV8-gof-PCSK9) and fed a Western diet for 16 weeks, showed significantly less plaque necrosis, increased fibrous caps and improved efferocytosis compared with AAV8-gof-PCSK9 injected wt controls. Additionally, hypercholesterolemic Mlkl-/- mice had a significant increase in proresolving mediators including resolvin D1 (RvD1) and a decrease in prostanoids including thromboxane in plaques and in vitro. We found that exuberant thromboxane released by NCs impaired the clearance of both apoptotic cells and NCs through disruption of oxidative phosphorylation in macrophages. Moreover, we found that NCs did not readily synthesize RvD1 and that exogenous administration of RvD1 to macrophages rescued NC-induced defective efferocytosis. RvD1 also enhanced the uptake of NCs via the activation of p-AMPK (AMP-activated protein kinase), increased fatty acid oxidation, and enhanced oxidative phosphorylation in macrophages. CONCLUSIONS: These results suggest that NCs derange resolution by limiting key SPMs and impairing the efferocytic repertoire of macrophages. Moreover, these findings provide a molecular mechanism for RvD1 in directing proresolving metabolic programs in macrophages and further suggests RvD1 as a potential therapeutic strategy to limit NCs in tissues. Graphic Abstract: A graphic abstract is available for this article.
Authors: Wei Tao; Arif Yurdagul; Na Kong; Wenliang Li; Xiaobo Wang; Amanda C Doran; Chan Feng; Junqing Wang; Mohammad Ariful Islam; Omid C Farokhzad; Ira Tabas; Jinjun Shi Journal: Sci Transl Med Date: 2020-07-22 Impact factor: 17.956
Authors: Brennan D Gerlach; Michael Marinello; Justin Heinz; Nicholas Rymut; Brian E Sansbury; Colin O Riley; Sudeshna Sadhu; Zeinab Hosseini; Yoko Kojima; Dale D Tang; Nicholas J Leeper; Matthew Spite; Margarida Barroso; Katey J Rayner; Gabrielle Fredman Journal: Cell Death Differ Date: 2019-06-20 Impact factor: 15.828
Authors: Ellen C Keeley; Han J Li; Christopher R Cogle; Eileen M Handberg; C Noel Bairey Merz; Carl J Pepine Journal: Am J Cardiol Date: 2021-10-30 Impact factor: 3.133
Authors: Nan Chiang; Miyuki Sakuma; Ana R Rodriguez; Bernd W Spur; Daniel Irimia; Charles N Serhan Journal: Blood Date: 2022-02-24 Impact factor: 22.113
Authors: Cassidy M R Blackburn; Robert M Schilke; Aimee E Vozenilek; Sunitha Chandran; Temitayo T Bamgbose; Brian N Finck; Matthew D Woolard Journal: Atherosclerosis Date: 2021-07-01 Impact factor: 6.847
Authors: Juan Salazar; Daniela Pirela; Manuel Nava; Ana Castro; Lissé Angarita; Heliana Parra; Samuel Durán-Agüero; Diana Marcela Rojas-Gómez; Néstor Galbán; Roberto Añez; Maricarmen Chacín; Andrea Diaz; Nelson Villasmil; Juan Bautista De Sanctis; Valmore Bermúdez Journal: Int J Mol Sci Date: 2022-03-15 Impact factor: 5.923